Skip to main content
SpringerLink
Log in

Chimeric B72.3 mouse/human (IgG1) antibody directs the lysis of tumor cells by lymphokine-activated killer cells

  • Original articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

Chimeric mouse/human B72.3 (cB72.3) antibodies having a human IgG1 (γ1) or IgG4 (γ4) constant region were compared to the native murine IgG1 B72.3 (nB72.3) monoclonal antibody (mAb) for their ability to participate with human effector cells in antibody-dependent cellular cytotoxicity (ADCC). Because the TAG-72 antigen recognized by B72.3 is poorly expressed on tissuecultured tumor cell lines, the xenografted OVCAR-3 human ovarian carcinoma ascites was used as a cytotoxicity target. The lytic activity of the cB72.3(γ1) mAb with peripheral blood lymphocytes was 1.5- to 50-fold greater than that of the nB72.3 mAb and usually the cB72.3(γ4) mAb. However, lymphocytes from some donors had similar ADCC activity with either the cB72.3(γ1) or cB72.3(γ4) mAb. The cB72.3(γ1) and the murine anti-colon carcinoma CO17-1A mAb had comparable activity in mediating ADCC against the OVCAR-3 tumor. Exposure of lymphoid cells to interleukin-2 (IL-2) (100–500 U/ml) for 24 h to generate lymphokine-activated killer (LAK) cells augmented ADCC mediated by the cB72.3(γ1) mAb 2- to 22-fold. By contrast, LAK cells from most donors expressed weak non-specific cytotoxicity against OVCAR-3 ascites tumor cells. The cB72.3(γ1), and to a lesser extent, the cB72.3(γ4) chimera also participated with monocytes in mediating ADCC, but the antibody-dependent lytic potency of monocytic effectors was much weaker than that of IL-2-activated lymphoid cells. These studies show that the cB72.3(γ1) mAb has appreciable ADCC-mediating properties, suggesting a potential role for its incorporation into treatment strategies utilizing adoptive killer cell and/or lymphokine therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Berinstein N, Levy R (1987) Treatment of a murine B cell lymphoma with monoclonal antibodies and IL-2. J Immunol 139: 971

    Google Scholar 

  2. Berinstein N, Starnes C, Levy R (1988) Specific enhancement of the therapeutic effect of anti-idiotype antibodies on a murine B cell lymphoma by IL-2. J Immunol 140: 2839

    Google Scholar 

  3. Bruggemann M, Williams GT, Bindon CI, Clark MR, Walker MR, Jefferis R, Waldmann H, Neuberger MS (1987) Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 166: 1351

    Google Scholar 

  4. Burton DR (1985) Immunoglobulin G: functional sites. Mol Immunol 22: 161

    Google Scholar 

  5. Cheung NK, Lazarus H, Miraldi FD, Abramowsky CR, Kallick S, Saarinen UM, Spitzer T, Strandjord SE, Coccia PF, Berger NA (1987) Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 5: 1430

    Google Scholar 

  6. Colcher D, Horan-Hand P, Nuti M, Schlom J (1981) A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci USA 78: 3199

    Google Scholar 

  7. Eisenthal A, Lafreniere R, Lefor AT, Rosenberg SA (1987) Effect of anti-B16 melanoma monoclonal antibody on established murine B16 melanoma liver metastases. Cancer Res 47: 2771

    Google Scholar 

  8. Eisenthal A, Cameron RB, Uppenkamp I, Rosenberg SA (1988) Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases. Cancer Res 48: 7140

    Google Scholar 

  9. Estaban JM, Colcher D, Sugarbaker P, Carrasquillo JA, Bryant G, Thor A, Reynolds JC, Larson SM, Schlom J (1987) Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered mAb B72.3. Int J Cancer 39: 50

    Google Scholar 

  10. Fischer DG, Hubbard WJ, Koren HS (1981) Tumor cell killing by freshly isolated peripheral blood monocytes. Cell Immunol 58: 426

    Google Scholar 

  11. Greiner JW, Horan Hand P, Noguchi P, Fisher PB, Pestka S, Schlom J (1984) Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte α-interferon treatment. Cancer Res 44: 3208

    Google Scholar 

  12. Greiner JW, Guadagni F, Smalley RV, Goldstein D, Borden EC, Schlom J (1990) Enhanced expression of tumor-associated antigens on human adenocarcinoma ascites cells as a result of intraperitoneal administration of interferon-gamma (IFN-γ) (abstract). American Association for Cancer Research, Washington, DC

    Google Scholar 

  13. Guadagni F, Schlom J, Johnston WW, Szpak CA, Goldstein D, Smallry R, Simpson JF, Borden EC, Pestka S, Greiner JW (1989) Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells. J Natl Cancer Inst 81: 502

    Google Scholar 

  14. Hamilton TC, Young RC, Louie KG, Behrens BC, McKoy WM, Grotzinger KR, Ozols RF (1984) Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Cancer Res 44: 5286

    Google Scholar 

  15. Hellstrom I, Hellstrom KE (1989) Antitumor antibodies for therapy. Nucl Med Biol 16: 613

    Google Scholar 

  16. Hellstrom I, Garrigues U, Lavie E, Hellstrom KE (1988) Antibodymediated killing of human tumor cells by attached effector cells. Cancer Res 48: 624

    Google Scholar 

  17. Herlyn DM, Koprowski H (1981) Monoclonal anticolon carcinoma antibodies in complement-dependent cytotoxicity. Int J Cancer 27: 769

    Google Scholar 

  18. Herlyn D, Koprowski H (1982) IgG2 a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc Natl Acad Sci USA 79: 4761

    Google Scholar 

  19. Herlyn M, Steplewski Z, Herlyn D, Koprowski H (1979) Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci USA 76: 1438

    Google Scholar 

  20. Herlyn D, Herlyn M, Steplewski Z, Koprowski H (1985) Monoclonal anti-human tumor antibodies of six isotypes in cytotoxic reactions with human and murine effector cells. Cell Immunol 92: 105

    Google Scholar 

  21. Honsik CJ, Jung G, Reisfeld RA (1986) Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin. Proc Natl Acad Sci USA 83: 7893

    Google Scholar 

  22. Horan Hand P, Colcher D, Salomon D, Ridge J, Noguchi P, Schlom J (1985) Influence of spatial configuration of carcinoma cell populations on the expression of a tumor-associated glycoprotein. Cancer Res 45: 833

    Google Scholar 

  23. Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadhan S, Carswell E, Melamed MR, Ottegen HF, Old LJ (1985) Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: A phase I trial patients with malignant melanoma. Proc Natl Acad Sci USA 82: 1242

    Google Scholar 

  24. Hutzell P, Kashmiri S, Colcher D, Primus J, Horan Hand P, Roselli M, Yarranton G, Callahan R, Schlom J (1990) Generation and characterization of a recombinant/chimeric B72.3 (human γ1) (submitted)

  25. Johnston WW, Szpak CA, Lottich SC, Thor A, Schlom J (1985) Use of monoclonal antibody (B72.3) as an immunocytochemical adjunct to diagnosis of adenocarcinoma in human effusions. Cancer Res 45: 1894

    Google Scholar 

  26. Kawase I, Komuta K, Hara H, Inoue T, Hosoe S, Ikeda T, Shirasaka T, Yokota S, Tanio Y, Masuno T, Kishimoto S (1988) Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin-2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity. Cancer Res 48: 1173

    Google Scholar 

  27. Klug TL, Sattler MA, Colcher D, Schlom J (1986) Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 72) on a novel pancarcinoma antigen (TAG-72). Int J Cancer 38: 661

    Google Scholar 

  28. Lastoria S, D'Amico P, Mansi L, Giordano GG, Rosiello R, Schlom J, Pace E, Panza N, Pacilio G, Salvatorie M (1988) A prospective imaging study of131I-B72.3 monoclonal antibody in patients with epithelial ovarian cancer: preliminary report. Nucl Med Commun 9: 347

    Google Scholar 

  29. Liu AY, Robinson RR, Hellstrom KE, Murray ED Jr, Chang CP, Hellstrom I (1987) Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci USA 84: 3439

    Google Scholar 

  30. Liu AY, Robinson RR, Murray ED Jr, Ledbetter JA, Hellstrom I, Hellstrom KE (1987) Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. J Immunol 139: 3521

    Google Scholar 

  31. LoBuglio AF, Saleh MN, Lee J, Khazaeli MB, Carrano R, Holden H, Wheeler RH (1988) Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. I. Clinical aspects. J Natl Cancer Inst 80: 932

    Google Scholar 

  32. LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB, Sun L, Ghrayeb J, Khazaeli MB (1989) Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA 86: 4220

    Google Scholar 

  33. Masucci G, Lindemalm C, Frodin JE, Hagstrom B, Mellstest H (1988) Effect of human blood mononuclear cell populations in antibody dependent cellular cytotoxicity (ADCC) using two murine (CO17-1A and Br55-2) and one chimeric (17-1A) monoclonal antibodies against a human colorectal carcinoma cell line (SW948). Hybridoma 7: 429

    Google Scholar 

  34. Mujoo K, Cheresh DA, Yang HM, Reisfeld RA (1987) Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res 46: 1098

    Google Scholar 

  35. Munn DH, Cheung NKV (1987) Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma. Cancer Res 47: 6600

    Google Scholar 

  36. Muraro R, Nuti M, Natali PG, Bigotti A, Simpson JF, Primus FJ, Colcher D, Greiner JW, Schlom J (1989) A monoclonal antibody (D612) with selective reactivity for malignant and normal gastro-intestinal epithelium. Int J Cancer 43: 598

    Google Scholar 

  37. Muul LM, Director EP, Hyatt CL, Rosenberg SA (1986) Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy. J Immunol Methods 88: 265

    Google Scholar 

  38. Nieroda CA, Mojzisik C, Sardi A, Farrar WB, Hinkle G, Siddiqi MA, Ferrara PJ, James A, Schlom J, Thurston MO, Martin EW Jr (1989) Staging of carcinoma of the breast using a hand-held gamma detecting probe and monoclonal antibody B72.3. Surg Gynecol Obstet 169: 35

    Google Scholar 

  39. Nishimura Y, Yokoyama M, Araki K, Udea R, Kudo A, Watanabe T (1987) Recombinant human mouse chimeric monoclonal antibody specific for common acute lymphocytic leukemia antigen. Cancer Res 47: 999

    Google Scholar 

  40. Ortaldo JR, Woodhouse C, Morgan AC, Herberman RB, Cheresh DA, Reisfeld R (1987) Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies. J Immunol 138: 3566

    Google Scholar 

  41. Riechmann L, Clark M, Waldmann H, Winter G (1988) Reshaping human antibodies for therapy. Nature 332: 323

    Google Scholar 

  42. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 316: 889

    Google Scholar 

  43. Scheinberg DA, Houghton AN (1987) Current status of antitumor therapy with monoclonal antibodies. Oncology 1: 31

    Google Scholar 

  44. Shaw DR, Khazaeli MB, LoBuglio AF (1988) Mouse/human chimeric antibodies to a tumor-associated antigen: biologic activity of the four human IgG subclasses. J Natl Cancer Inst 80: 1553

    Google Scholar 

  45. Sheer DG, Schlom J, Cooper HL (1988) Purification and composition of the human tumor-associated glycoprotein (TAG-72) defined by monoclonal antibodies CC49 and B72.3. Cancer Res 48: 6811

    Google Scholar 

  46. Sosman JA, Kohler PC, Hank J, Moore KH, Bechhofer R, Storer B, Sondel PM (1988) Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity. J Natl Cancer Inst 80: 60

    Google Scholar 

  47. Steplewski Z, Sun LK, Shearman CW, Ghrayeb J, Daddona P, Koprowski H (1988) Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc Natl Acad Sci USA 85: 4852

    Google Scholar 

  48. Thor A, Ohuchi N, Szpak CA, Johnston WW, Schlom J (1986) Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined monoclonal antibody B72.3. Cancer Res 46: 3118

    Google Scholar 

  49. Thor A, Viglione MJ, Muraro R, Ohuchi N, Schlom J, Gorstein F (1987) Monoclonal antibody B72.3 reactivity with human endometrium: A study of normal and malignant tissues. Int J Gynecol Pathol 6: 235

    Google Scholar 

  50. Tong AW, Lee JC, Wang RM, Ordonez G, Stone MJ (1989) Augmentation of lymphokine-activated killer cell cytotoxicity by monoclonal antibodies against human small cell lung carcinoma. Cancer Res 49: 4103

    Google Scholar 

  51. Welt S, Carswell EA, Vogel CW, Oettgen HF, Old LJ (1987) Immune and nonimmune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialoganglioside GD3 on surface of melanoma cells. Clin Immunol Immunopathol 45: 214

    Google Scholar 

  52. Whittle N, Adair J, Lloyd C, Jenkins L, Devine J, Schlom J, Raubitschek A, Colcher D, Bodmer M (1987) Expression in COS cells of a mouse-human chimeric B72.3 antibody. Protein Engineering 1: 499

    Google Scholar 

  53. Wiltrout RH, Taramelli D, Holden HT (1981) Indium-111 assay of macrophage-mediated cytolysis. In: Herscowitz HB (ed) Manual of macrophage methodology: collection, characterization, and function. Dekker, New York, p 531

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Tumor Immunology and Biology, National Cancer Institute, 20 892, Bethesda, MD, USA

    F. James Primus, Tribhuvan K. Pendurthi, Paula Hutzell, Syed Kashmiri, Dale C. Slavin, Robert Callahan & Jeffrey Schlom

Authors
  1. F. James Primus
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tribhuvan K. Pendurthi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paula Hutzell
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Syed Kashmiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dale C. Slavin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Robert Callahan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jeffrey Schlom
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Offprint requests to: J. Schlom, to whom reprint requests should be sent at 9000 Rockville Pike, Building 10, Room 8B07, Bethesda, MD 20892, USA

Rights and permissions

Reprints and permissions

About this article

Cite this article

Primus, F.J., Pendurthi, T.K., Hutzell, P. et al. Chimeric B72.3 mouse/human (IgG1) antibody directs the lysis of tumor cells by lymphokine-activated killer cells. Cancer Immunol Immunother 31, 349–357 (1990). https://doi.org/10.1007/BF01741406

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01741406

Keywords

Search

Navigation